BNP Paribas Financial Markets Has $580,000 Stake in DENTSPLY SIRONA Inc. (NASDAQ:XRAY)

BNP Paribas Financial Markets decreased its holdings in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 5.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 30,561 shares of the medical instruments supplier’s stock after selling 1,933 shares during the quarter. BNP Paribas Financial Markets’ holdings in DENTSPLY SIRONA were worth $580,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Riverview Trust Co acquired a new stake in shares of DENTSPLY SIRONA during the 4th quarter worth approximately $26,000. MassMutual Private Wealth & Trust FSB grew its position in shares of DENTSPLY SIRONA by 648.4% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,422 shares of the medical instruments supplier’s stock worth $27,000 after buying an additional 1,232 shares during the period. UMB Bank n.a. grew its position in shares of DENTSPLY SIRONA by 60.8% during the 4th quarter. UMB Bank n.a. now owns 1,492 shares of the medical instruments supplier’s stock worth $28,000 after buying an additional 564 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in shares of DENTSPLY SIRONA by 700.0% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 1,792 shares of the medical instruments supplier’s stock worth $33,000 after buying an additional 1,568 shares during the period. Finally, Quarry LP grew its position in shares of DENTSPLY SIRONA by 25.7% during the 4th quarter. Quarry LP now owns 3,816 shares of the medical instruments supplier’s stock worth $72,000 after buying an additional 780 shares during the period. Institutional investors and hedge funds own 95.70% of the company’s stock.

DENTSPLY SIRONA Stock Performance

Shares of XRAY opened at $15.47 on Friday. The company has a debt-to-equity ratio of 0.72, a quick ratio of 0.84 and a current ratio of 1.25. DENTSPLY SIRONA Inc. has a twelve month low of $12.16 and a twelve month high of $28.25. The firm’s 50 day moving average price is $14.47 and its two-hundred day moving average price is $17.13. The firm has a market cap of $3.08 billion, a P/E ratio of -7.47, a PEG ratio of 1.80 and a beta of 0.92.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.29 by $0.14. DENTSPLY SIRONA had a negative net margin of 10.59% and a positive return on equity of 12.62%. The firm had revenue of $879.00 million for the quarter, compared to analyst estimates of $854.75 million. During the same quarter in the previous year, the firm posted $0.42 earnings per share. The business’s revenue was down 7.8% on a year-over-year basis. On average, analysts forecast that DENTSPLY SIRONA Inc. will post 1.84 EPS for the current fiscal year.

DENTSPLY SIRONA Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, April 11th. Stockholders of record on Friday, March 28th were given a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a dividend yield of 4.14%. The ex-dividend date was Friday, March 28th. DENTSPLY SIRONA’s dividend payout ratio is presently -14.10%.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on XRAY shares. Mizuho decreased their price objective on shares of DENTSPLY SIRONA from $21.00 to $18.00 and set a “neutral” rating for the company in a report on Thursday, March 13th. Piper Sandler decreased their price objective on shares of DENTSPLY SIRONA from $20.00 to $16.00 and set a “neutral” rating for the company in a report on Wednesday, April 30th. UBS Group decreased their price objective on shares of DENTSPLY SIRONA from $27.00 to $25.00 and set a “buy” rating for the company in a report on Friday, May 9th. Wall Street Zen upgraded shares of DENTSPLY SIRONA from a “hold” rating to a “buy” rating in a report on Friday, May 9th. Finally, Needham & Company LLC restated a “hold” rating on shares of DENTSPLY SIRONA in a report on Thursday, March 13th. Eleven analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $20.36.

Insider Transactions at DENTSPLY SIRONA

In other DENTSPLY SIRONA news, Director Gregory T. Lucier acquired 15,142 shares of the business’s stock in a transaction dated Monday, March 3rd. The shares were acquired at an average price of $16.51 per share, with a total value of $249,994.42. Following the completion of the transaction, the director now directly owns 81,971 shares in the company, valued at $1,353,341.21. This trade represents a 22.66% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.52% of the stock is currently owned by insiders.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.